Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Equity

Seres Therapeutics (MCRB) Equity Average (2016 - 2025)

Historic Equity Average for Seres Therapeutics (MCRB) over the last 11 years, with Q3 2025 value amounting to $38.3 million.

  • Seres Therapeutics' Equity Average rose 22136.33% to $38.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.3 million, marking a year-over-year increase of 22136.33%. This contributed to the annual value of -$15.5 million for FY2024, which is 880.76% up from last year.
  • Latest data reveals that Seres Therapeutics reported Equity Average of $38.3 million as of Q3 2025, which was up 22136.33% from $41.7 million recorded in Q2 2025.
  • Over the past 5 years, Seres Therapeutics' Equity Average peaked at $159.2 million during Q1 2021, and registered a low of -$73.4 million during Q2 2024.
  • For the 5-year period, Seres Therapeutics' Equity Average averaged around $38.6 million, with its median value being $38.3 million (2025).
  • Per our database at Business Quant, Seres Therapeutics' Equity Average surged by 38957.56% in 2021 and then crashed by 94307.84% in 2024.
  • Over the past 5 years, Seres Therapeutics' Equity Average (Quarter) stood at $153.6 million in 2021, then plummeted by 74.49% to $39.2 million in 2022, then plummeted by 176.54% to -$30.0 million in 2023, then soared by 162.86% to $18.9 million in 2024, then surged by 103.29% to $38.3 million in 2025.
  • Its Equity Average stands at $38.3 million for Q3 2025, versus $41.7 million for Q2 2025 and $32.1 million for Q1 2025.